CEPI puts $25M into Rift Valley fever vaccine; Gates invests in AI for scientists in Africa in equity bid

10 Oct 2023

Vaccine

Plus, Olema and Novartis update an agreement for a breast cancer trial, and Roche shares long-term data for Vabysmo in macular edema. CEPI puts $25M into vaccine for Rift Valley fever: The Coalition for Epidemic Preparedness Innovation is giving $25.9 million to Wageningen Bioveterinary Research to advance a live-attenuated vaccine for Rift Valley fever into a Phase I/IIa trial. CEPI said Tuesday that heavy rain and flooding are linked to outbreaks of the virus, which is primarily spread by mosquitoes in sub-Saharan Africa. “A RVF vaccine will contribute to preparedness for potential virus emergence in yet unaffected regions like Europe,” WBVR’s Paul Wichgers Schreur said in a statement. — Jaimy Lee

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Olema Pharmaceuticals, Inc.

Novartis AG

Roche Holding AG

Indications

Breast CancerMacular EdemaRift Valley Fever

Targets

Drugs

Inactivated Rift Valley fever virus vaccine(United States Army Medical Research Institute of Infectious Diseases)FaricimabLive attenuated vaccine(United States Army Medical Research Institute of Infectious Diseases)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.